Single Dose of Antibiotic as Effective as Multiple Doses for Treating Early Syphilis, Study Finds

A new clinical trial reveals that a single injection of benzathine penicillin G is as effective as multiple doses for treating early syphilis, offering a simpler treatment option and potentially improving patient adherence.
Recent clinical research has demonstrated that a single injection of the antibiotic benzathine penicillin G (BPG) can effectively treat early syphilis, matching the success rate of the traditional three-dose regimen. The study, published in the New England Journal of Medicine, involved 249 participants across ten U.S. sites, most of whom were men and a significant portion living with HIV.
Participants were randomly assigned to receive either one intramuscular injection of 2.4 million units of BPG or three weekly injections of the same dosage. Follow-up blood tests measured the serologic response to treatment after six months. Results showed that 76% of the single-dose group exhibited successful treatment responses, compared to 70% in the three-dose group. The difference was not statistically significant, indicating that the single-dose regimen is equally effective.
This finding has important implications for patient care, as the single-dose approach simplifies treatment and could improve adherence, especially given the burden associated with multiple clinic visits. However, one participant developed neurosyphilis shortly after treatment initiation and was excluded from the analysis. The study also reported three serious adverse events unrelated to the medication.
Syphilis remains a significant public health concern, with increasing cases reported in the U.S., including over 200,000 new infections in 2023. If untreated, syphilis can cause severe complications, including neurological damage, organ damage, and adverse pregnancy outcomes. The antibiotic BPG, a mainstay treatment for syphilis, faces global shortages, though it is currently being imported into the U.S. to address supply issues.
The research highlights the potential for a more streamlined treatment strategy, which could lead to better patient outcomes and easier management of syphilis cases. Further studies are needed to evaluate whether this abbreviated regimen can be effectively applied across all stages of syphilis, including latent and late stages.
Source: https://medicalxpress.com/news/2025-09-dose-antibiotic-early-syphilis-doses.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative AI Technique Illuminates How Gamma-Secretase Targets Molecules in Alzheimer's Disease
A novel AI approach has uncovered the molecular recognition logic of gamma-secretase, an enzyme linked to Alzheimer's disease, unveiling new potential targets and enhancing drug development strategies.
Germany's BioNTech Acquires CureVac to Accelerate Cancer Research Using mRNA Technology
Germany's BioNTech is acquiring CureVac for $1.25 billion to strengthen its mRNA technology platform and accelerate the development of innovative cancer immunotherapies, marking a significant move in biotech research.
Understanding the Link Between Tylenol Use During Pregnancy and Autism: Distinguishing Correlation from Causation
Recent studies explore the potential link between Tylenol use during pregnancy and autism, emphasizing the distinction between association and causation in scientific research. Current evidence remains inconclusive, urging medical guidance and further investigation.
Rise in Emergency Visits by Uninsured Children in Texas Following End of COVID Federal Support
A recent study shows a 45% increase in uninsured children's emergency department visits in Texas after COVID-era federal funding ended, highlighting significant healthcare access concerns.